Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: J Neurochem. 2020 Jul 22;156(6):988–1002. doi: 10.1111/jnc.15116

Figure 1.

Figure 1.

A schematic of the workflow used to study the proteomic changes in the brain of AD patients. The brain samples were homogenized in liquid nitrogen and lysed in 2% SDS buffer. Brain proteomes from cognitively normal individuals were compared with that of AD patients using a TMT-based quantitative proteomics approach in the discovery step. Validation was carried out using parallel reaction monitoring (PRM) assays for a subset of molecules that were found to be altered in abundance in AD.